Tahir Amin
@tahiramin.bsky.social
📤 1344
📥 185
📝 307
CEO
@imakglobal.bsky.social
. Co-author of PHARMA MONOPOLY
https://bit.ly/3OuK62N
pinned post!
I’m excited to share that my first book, Pharma Monopoly: The Battle for the Future of Medicines, co-written with Rohit Malpani, will be published in March in the UK/Europe and May in the U.S.
5 months ago
2
5
4
Pharma Monopoly spotted at
@rizzolibooks.bsky.social
in NYC. If you’re in New York, I’ll be in conversation with A. Kayum Ahmed on Thursday, June 11 at 6PM at The People's Forum for the U.S launch of Pharma Monopoly. RSVP here:
docs.google.com/forms/d/e/1F...
3 days ago
0
0
0
SCOTUS's 9-0 ruling in Hikma v. Amarin prevented an attempt to dilute how skinny labelling as conceived was intended to work, but that this case even got this far shows where we are...
www.supremecourt.gov/opinions/25p...
loading . . .
https://www.supremecourt.gov/opinions/25pdf/24-889_5i36.pdf
3 days ago
1
0
0
Thank you Sonali Kolhatkar for having me on the show to talk about drug pricing and my new co-authored book, Pharma Monopoly.
risingupwithsonali.com/heres-how-we...
loading . . .
6 days ago
0
1
1
What makes this more striking is that it doesn't even include Zepbound (Eli Lilly's higher-dose tirzepatide product), which now makes as much revenue as Mounjaro in the U.S.
10 days ago
1
1
1
It was a pleasure to speak with Aisha Nyandoro for
@forbes.com
on the occasion of the U.S release of Pharma Monopoly.
www.forbes.com/sites/aishan...
loading . . .
A Former IP Attorney On Why Drug Pricing Is Really About Power
Pharmaceutical monopolies, patent law, and global health access shaping drug pricing, power, and inequities in the U.S. and worldwide.
https://www.forbes.com/sites/aishanyandoro/2026/05/26/a-former-ip-attorney-on-why-drug-pricing-is-really-about-power/
11 days ago
0
2
2
reposted by
Tahir Amin
Initiative for Medicines, Access & Knowledge
12 days ago
Join us for two upcoming events on occasion of
@tahiramin.bsky.social
's new co-authored book, Pharma Monopoly! Details below.
1
2
2
In this excerpt from Chapter 5 of Pharma Monopoly, titled “The Innovation Trap,” we explain how the pharmaceutical industry has weaponized the word “innovation” to ensure a perpetual novelty of knowledge that should be in the public domain.
www.statnews.com/2026/05/26/h...
loading . . .
The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
https://www.statnews.com/2026/05/26/humira-patents-abbvie-innovation-pharma-monopoly-excerpt/
12 days ago
0
2
2
reposted by
Tahir Amin
James Packard Love
12 days ago
@tahiramin.bsky.social
and Rohit Malpani. The innovation trap: How pharma weaponizes a word to extend monopolies
www.statnews.com/2026/05/26/h...
via
@statnews.com
loading . . .
The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
https://www.statnews.com/2026/05/26/humira-patents-abbvie-innovation-pharma-monopoly-excerpt/
0
2
2
Pharma Monopoly: The Battle for the Future of Medicines, co-authored with Rohit Malpani, is now on sale in the U.S.
12 days ago
1
2
1
reposted by
Tahir Amin
Page One Media
13 days ago
Happy publication day, Tahir! Billions are denied affordable medicine by outdated patent rules and neoliberal policies. In PHARMA MONOPOLY,
@tahiramin.bsky.social
and Rohit Malpani expose how governments ceded control to pharmaceutical giants—and how we can undo the damage.
1
2
3
reposted by
Tahir Amin
Madhu Pai, MD, PhD
12 days ago
“The business model of using patents and the language of innovation to justify prolonged patent monopolies that keep knowledge privatized for longer than necessary is endemic across the pharmaceutical industry”
@tahiramin.bsky.social
@statnews.com
www.statnews.com/2026/05/26/h...
loading . . .
The innovation trap: How pharma weaponizes a word to extend monopolies
“Just because a company invests does not mean it has invented anything novel,” Tahir Amin and Rohit Malpani write in this excerpt from “Pharma Monopoly.”
https://www.statnews.com/2026/05/26/humira-patents-abbvie-innovation-pharma-monopoly-excerpt/
0
7
9
reposted by
Tahir Amin
Sarah Russo
16 days ago
Read an excellent excerpt from
@tahiramin.bsky.social
’s new book: PHARMA MONOPOLY in
@truthdig.com
👇👇👇
add a skeleton here at some point
0
5
4
reposted by
Tahir Amin
Truthdig
17 days ago
A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus.
www.truthdig.com/articles/at-...
loading . . .
'Pharma Monopoly' Details Why Trump’s Claims About Tackling the Prescription Drug Price Crisis Are Bogus
A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus.
https://www.truthdig.com/articles/at-the-mercy-of-big-pharma/
0
4
2
@truthdig.com
ran an excerpt from a chapter in my co-authored book, Pharma Monopoly, that traces how the drug industry and U.S foreign policymakers became partners in expanding the industry’s monopoly power.
www.truthdig.com/articles/at-...
loading . . .
'Pharma Monopoly' Details Why Trump’s Claims About Tackling the Prescription Drug Price Crisis Are Bogus
A new book explains why drugs cost so much in the United States — and why Trump’s claims about addressing the crisis are bogus.
https://www.truthdig.com/articles/at-the-mercy-of-big-pharma/
16 days ago
0
4
2
My latest op-ed in
@marketwatch.com
. 40% of the world will soon have access to Ozempic and Wegovy generics. But not Americans. And we have our Reagan-era drug laws to thank for that.
www.marketwatch.com/story/canada...
loading . . .
Canada and India now have generic Wegovy. Here’s why the U.S. doesn’t.
Over the next year, countries that are home to 40% of the world’s population are set to get access to Ozempic and Wegovy generics that could cost as little as $15 a month.
https://www.marketwatch.com/story/canada-and-india-now-have-generic-wegovy-heres-why-the-u-s-doesnt-db18b6b7
17 days ago
0
8
4
This slide is from Definium's recent investor call. It shows how they intend to build a monopoly around a derivative of LSD they've dubbed DT120 ODT despite the active ingredient, LSD, being nearly 90 years old.🧵
17 days ago
1
1
1
I'll be in conversation with A. Kayum Ahmed on June 11 at The People's Forum in NYC to discuss my newly co-authored book, Pharma Monopoly. Please join us. RSVP below.
docs.google.com/forms/d/e/1F...
loading . . .
Pharma Monopoly NYC Book Launch RSVP
Please fill out this form to register for the event on June 11, 2026 at 6:00pm at The People's Forum.
https://docs.google.com/forms/d/e/1FAIpQLSeNPI8C5x0aH-ioAyxdNjd8XF6V3RMCQKGQjF9BTlt5i4Bj0A/viewform
18 days ago
0
0
0
“A relatively small share of Americans stand to directly benefit from these moves...But for many Americans struggling with a range of surging costs, the president’s drug pricing moves have not translated into direct savings."
www.nytimes.com/2026/05/18/b...
loading . . .
TrumpRx Adds Generic Drugs, With Mark Cuban, GoodRx and Amazon
https://www.nytimes.com/2026/05/18/business/trumprx-generic-drugs-mark-cuban.html
20 days ago
0
0
0
Good to see a current Senate candidate and 2028 hopeful focus on drug pricing and pharma lobbying. If
@ossoff.bsky.social
wants to get specific about policies that are both popular and get to the root of the drug pricing problem, he should join the bipartisan momentum for patent reform.
add a skeleton here at some point
27 days ago
2
0
0
The ruse of neoliberalism’s “rules-based order” is more exposed than it’s ever been. In Hindu Business Line, I pull on themes from my upcoming book to explain how countries like India can use this moment to build systems that truly serve the public good.
www.thehindubusinessline.com/specials/pul...
loading . . .
‘Free markets’ and shackled access to medicines
Explore the ongoing struggle for affordable medicine access amidst global pharmaceutical monopolies and the need for systemic change.
https://www.thehindubusinessline.com/specials/pulse/free-markets-and-shackled-access-to-medicines/article70917312.ece
28 days ago
0
0
0
Good that both parties are connecting affordability to root causes. And good that pharma is losing some "friends". If we really want to see lower drug prices, we’ll need to see more “unfriending” of the pharmaceutical lobby, especially within the PTO and FDA.
about 1 month ago
0
0
0
reposted by
Tahir Amin
Madhu Pai, MD, PhD
about 1 month ago
Coming out this month! Pharma Monopoly: The Battle for the Future of Medicines
@tahiramin.bsky.social
& Rohit Malpani (two respected scholars of access to meds)
www.politybooks.com/bookdetail?b...
loading . . .
Pharma Monopoly: The Battle for the Future of Medicines
Pharma Monopoly: The Battle for the Future of Medicines, It is no secret that billions of people across the world lack the freedom and right to access life-saving medicines
https://www.politybooks.com/bookdetail?book_slug=pharma-monopoly-the-battle-for-the-future-of-medicines--9781509558322
0
3
1
reposted by
Tahir Amin
Initiative for Medicines, Access & Knowledge
about 2 months ago
Why is the price of the cancer drug Revlimid increasing even though lower-cost generics are on the market? Because Celgene/BMS used a new kind of “pay-for-delay” deal that is harder for regulators to catch: a “limited-volume settlement.”
loading . . .
2
2
2
reposted by
Tahir Amin
Patrick Durisch
about 2 months ago
Thank you
@tahiramin.bsky.social
@imakglobal.bsky.social
for supporting
@fr.publiceye.ch
in our patent analysis of cancer drug
#Keytruda
, in conjunction with
@icij.org
, unveiling MSD's gaming of the patent systems to maintain overinflated prices & delay competition
www.publiceye.ch/en/topics/ph...
add a skeleton here at some point
2
21
12
Our team at
@imakglobal.bsky.social
provided patenting data to
@icij.org
for their investigation into Merck's Keytruda. The ICIJ reviewed the data and built a visualization of Merck’s patent portfolio.
loading . . .
How Merck uses patents to help maintain Keytruda's exorbitant price - ICIJ
Explore the U.S. patents Merck deploys to stymie competition and keep revenues for its blockbuster cancer drug flowing as long as possible.
https://www.icij.org/investigations/cancer-calculus/keytruda-evergreening-patents-merck/
about 2 months ago
1
9
3
A team of journalists at the
@icij.org
and 47 media partners in 37 countries just published a yearlong investigation into how Merck built its global Keytruda monopoly.
add a skeleton here at some point
about 2 months ago
0
12
4
Our team at
@imakglobal.bsky.social
released a new brief, The Monopoly Extension Menu.🧵
reports.i-mak.org/monopoly-ext...
loading . . .
The Monopoly Extension Menu | I-MAK
High prescription drug prices in the United States are often explained as an unavoidable consequence of investment in biomedical progress. Yet across therapeutic areas, delayed competition more often ...
https://reports.i-mak.org/monopoly-extension-menu/
about 2 months ago
1
2
1
reposted by
Tahir Amin
Nick Dearden
2 months ago
Really looking forward to chatting to my old friend
@tahiramin.bsky.social
about his new book Pharma Monopoly. 27.04 in London 👇
www.eventbrite.co.uk/e/tahir-amin...
loading . . .
https://www.eventbrite.co.uk/e/tahir-amin-in-conversation-tickets-1986993710677?utm-campaign=social&utm-content=attendeeshare&utm-medium=discovery&utm-term=listing&utm-source=cp&aff=ebdsshcopyurl
0
1
1
GLP-1 sales accounted for about 74% of Novo’s total revenue last year. Novo will generate an est. $94B from U.S. GLP-1 sales between 2018-2026. They’re expected to return up to $68B, or 72 cents of every dollar, to shareholders via buybacks and dividends, during that same period.
2 months ago
0
0
0
Important reporting by The New York Times. The primary patents on Novo Nordisk’s Ozempic and Wegovy should expire today. Generics are expected to launch in India shortly after, followed by China, Canada, Brazil, Turkey, and South Africa. 1/
www.nytimes.com/2026/03/19/h...
loading . . .
Ozempic Is About to Go Generic for Billions of People
https://www.nytimes.com/2026/03/19/health/ozempic-wegovy-generic-india-china-canada.html
3 months ago
1
0
1
In his SOTU, President Trump claimed he is “ending the wildly inflated costs of prescription drugs." "Other presidents tried to do it but they never could,” he said. “I got it done.” TrumpRX is a gimmick. 🧵
loading . . .
3 months ago
1
0
0
Tech and pharma will pour money into AI-related lobbying this year, especially to shape IP policy. Tech will push for carve outs while pharma will demand we expand what counts as patentable to include AI-assisted discoveries so they can generate more follow-on patents.
4 months ago
1
1
0
Sen Coons: "I was in-house counsel to a global company that had a very large patent estate.” Fox in the henhouse comes to mind.
loading . . .
4 months ago
0
0
0
Good point by Tim Wu. The pharma market is especially prone to extraction because pharma patents/IP confer power that patents/IP in other fields of technology simply don’t.
loading . . .
4 months ago
1
0
0
Excellent substack from Thomas Krause. A linear, logical explanation of a simple truth: creating patent thickets is standard practice and patients pay the price.
substack.com/home/post/p-...
loading . . .
Yes C4IP, There Are Patent Thickets
Responding to Patent-Thicket Deniers
https://substack.com/home/post/p-187002763
4 months ago
0
1
0
reposted by
Tahir Amin
Sarah Russo
4 months ago
Very excited to be partnering with
@tahiramin.bsky.social
,
@miracleworkerpr.bsky.social
,
@lauradigiovine.bsky.social
and
@politybooks.bsky.social
books to usher PHARMA MONOPOLY into the world. Media friends, let me know if we can send you a galley.
add a skeleton here at some point
0
2
2
reposted by
Tahir Amin
Initiative for Medicines, Access & Knowledge
4 months ago
Medicare's Drug Price Negotiation Program recently announced the 15 drugs selected for its third round of negotiations. As the program expands, its success is in danger of being undercut by legislators giving drug companies new ways to extend their monopolies. 🧵
www.statnews.com/2026/01/27/m...
loading . . .
15 new drugs added to Medicare price negotiations
The Trump administration released the next 15 drugs subject to Medicare price negotiation, including for the first time treatments administered in doctor offices.
https://www.statnews.com/2026/01/27/medicare-drug-price-negotiations-third-round-targets-15-drugs/
2
2
1
“Drug companies, including the 16 that made deals [with the Trump administration], raised the prices of 872 brand-name drugs in the first two weeks of 2026”
www.npr.org/2026/01/16/n...
loading . . .
Trump struck deals with 16 drug companies. But they're still raising prices this year
All 16 drug companies that inked deals with the Trump administration over the past few months still raised some of their prices for 2026.
https://www.npr.org/2026/01/16/nx-s1-5678915/trumprx-pharma-drug-price-deals-list-prices
4 months ago
0
3
2
Price hikes by pharma companies between Jan 1 and Jan 9
4 months ago
0
1
0
I’m excited to share that my first book, Pharma Monopoly: The Battle for the Future of Medicines, co-written with Rohit Malpani, will be published in March in the UK/Europe and May in the U.S.
5 months ago
2
5
4
This is called product hopping.
5 months ago
1
2
1
“Moving patients to the newer version is key for Bristol because it has a longer patent life than the mainstay version of the drug that’s infused…Bristol also hopes the newer version can avoid being part of price negotiations under the Inflation Reduction Act…”
add a skeleton here at some point
5 months ago
1
0
0
We will continue to fight for that world that David dreamed of, a world where lifesaving medicines can be within reach of every patient. Rest in power, David.
add a skeleton here at some point
5 months ago
0
1
1
He should launch a generic drug company and take on big pharma patent monopolies next.
6 months ago
0
1
0
Get ready for pharma companies to ratchet up “lifecycle management” strategies under the language of “innovation” to squeeze even more $ from their blockbusters as they all chase the new $1T benchmark
6 months ago
0
1
0
reposted by
Tahir Amin
Initiative for Medicines, Access & Knowledge
6 months ago
👏 NEWS: Teva removes over 200 improper Orange Book patent listings under pressure from the FTC. 🔗
www.fiercepharma.com/pharma/ftc-c...
add a skeleton here at some point
0
5
3
Good to see the FTC continue Lina Khan's policies of enforcement against improper patent listings
6 months ago
0
1
0
Our team at
@imakglobal.bsky.social
partnered with
@statnews.com
to analyze our
@fandmpoll.bsky.social
survey on how the public views drug pricing. What stands out is how Americans across the political spectrum support patent reform.
add a skeleton here at some point
6 months ago
0
0
0
This is true. Look at AbbVie’s CEO. It says a lot about a pharma company's priorities when their CEO's bio focuses entirely on financial achievements.
add a skeleton here at some point
6 months ago
1
2
1
The TRIPS Agreement has nothing to do with free trade and everything to do with protecting corporate monopolies. It’s why pharma was able to block South Africa from purchasing HIV/AIDS treatments in the '90s and why Moderna and J&J were able to monopolize COVID vaccines.
loading . . .
6 months ago
0
1
1
Load more
feeds!
log in